Cancer is not a disease of rogue cells growing faster than normal — it is a Darwinian evolutionary system governed by selection pressure, and the dominant strategy of maximum-tolerated-dose chemotherapy is actively selecting for resistance while eliminating the very sensitive cells that could otherwise suppress resistant ones.
2
Adaptive therapy — giving just enough drug to push the tumor to 50% of pre-treatment volume, then withdrawing and letting sensitive cells rebound — exploits the fitness cost of resistance: in a pilot prostate cancer trial, the adaptive arm achieved 30-month median time-to-progression versus 14 months for standard of care, with four patients still cycling at five years.
3
The extinction vortex logic borrowed from ecology suggests that once a tumor is fragmented into small, isolated subpopulations, a sequence of perturbations — not a single magic bullet — can drive those remnant cells to extinction through stochastic effects and Allee dynamics that large populations are immune to.
4
Resistance is not an accident: pesticide farmers and oncologists commit the same error — maximum-dose application selects for the resistant minority, clears competitive suppression from sensitive cells, and hands the field to a population that will be permanently uncontrollable.
Protocols
Concrete recipes — what, when, how much, and why
6 items
Adaptive therapy (PSA-guided cycling) for metastatic prostate cancer
WhatInitiate enzalutamide or abiraterone at standard dose. Monitor PSA monthly. When PSA falls to 50% of pre-treatment value, STOP therapy — do not wait for radiographic confirmation. Restart when PSA returns to pre-treatment level. Cycle indefinitely.
WhenAt diagnosis of metastatic castration-sensitive prostate cancer, as first-line androgen deprivation strategy.
DoseStandard enzalutamide or abiraterone dose during treatment windows; the 50% PSA reduction is the withdrawal trigger, not radiographic complete response.
For whomMen with newly diagnosed metastatic prostate cancer, especially those willing to accept a cycling protocol with close PSA monitoring. Requires an oncologist comfortable with non-standard protocols.
WhyContinuous maximum-dose ADT eliminates sensitive cells, removes competitive suppression of resistant cells, and accelerates inevitable castration resistance. Cycling preserves a sensitive-cell population whose 7-fold fitness advantage over resistant cells suppresses and, over three optimal cycles, can extinguish the resistant clone.
CaveatsRequires monthly PSA monitoring and willingness to halt therapy at 50% reduction. Radiographic confirmation of response should NOT delay drug withdrawal — the insurance-driven lag was the primary failure mode in the pilot trial. Currently available at limited academic centers.
The pilot trial enrolled 20 patients. Median time to progression was 30 months versus 14 for standard care. Four patients remain on therapy at five years — essentially unheard-of in metastatic castration-sensitive prostate cancer. The model predicts that perfect cycle execution (pure PSA-guided, no radiographic lag) would have produced indefinite tumor control in all patients. The trial drug is now off-patent, removing commercial incentive to study the protocol further.
Mechanism
Sensitive cells have a 7-fold fitness advantage over resistant cells in a drug-free environment because resistance machinery (efflux pumps, DNA repair, metabolic reprogramming) carries a metabolic cost. When drug is absent, sensitive cells outcompete and suppress resistant cells. Three optimal cycles drive the resistant subpopulation to extinction via stochastic and competitive dynamics.
we gave the drug until the tumor responded to 50 of its pre-treatment value, pulled it away, let the tumor come back up. The sensitive guys are supposed to come back up and grow at the expense of the resistance.
Also said
“the models predicted that every patient in both cohorts in this study could have had control of the tumor indefinitely”— The model result: imperfect cycling still beat standard of care; perfect cycling was theoretically curative.
Sequential extinction protocol: first-strike cytoreduction plus immediate second and third perturbation while tumor is fragmented
WhatWhen a first-line therapy drives a tumor to near-undetectable levels, do NOT continue the same therapy. Immediately pivot to a second agent targeting a different mechanism. Then a third. The goal is to exploit the fragmented small-population state before the tumor reconstitutes cooperative behavior and rebuilds resistance.
WhenImmediately after confirming near-complete first-line response, before the tumor population can re-expand.
DoseSecond- and third-line agents at standard doses; the timing imperative is the critical variable, not the dose.
For whomAny cancer patient who achieves a major or complete response to first-line therapy — metastatic prostate cancer on ADT (PSA normalization in 90%+), small cell lung cancer (routinely achieves near-complete radiographic response), ovarian cancer, childhood leukemia (already uses this approach as standard of care).
WhyLarge tumors have sufficient heterogeneity that most combinations will fail to eradicate all resistant clones. At very small population sizes after neoadjuvant therapy, stochastic effects, Allee-effect collapse of cooperative survival behaviors, and reduced genetic heterogeneity make the population acutely vulnerable to sequential perturbations that individually would not be sufficient.
CaveatsRequires oncologist willingness to abandon standard 'continue until progression' approach. Combination toxicity must be assessed. The model does not specify which second-line agents to use — the principle is sequential perturbation, not a fixed drug sequence.
Gatenby uses pediatric leukemia cure as proof of concept: induction drives leukemia to apparent bone marrow clearance, then immediately switches to consolidation and maintenance with entirely different drug classes. Adult oncology abandoned this approach because there is nothing visible to measure — but that is precisely the correct moment to act, as the small fragmented population is maximally vulnerable. Waiting for visible disease re-growth surrenders the window.
Mechanism
At small population sizes, stochastic fluctuations in birth and death rates can drive extinction improbable in large populations. Allee effects: cancer cells rely on group behaviors (cooperative VEGF secretion, collective immune evasion, extracellular matrix construction) that require minimum group size. Fragmentation disrupts these behaviors.
it's not a boxing match it's a knife fight. When you knock your opponent down you don't stand back and wait — you go attack. We've called that an extinction approach.
Sequential drug introduction timed to tumor population size reduction
WhatWhen multiple active agents exist for a cancer, do not give them simultaneously. Give drug A first until the tumor is substantially reduced. Introduce drug B when the population is at tens of millions of cells rather than tens of billions. The probability of pre-existing double-resistance is exponentially lower in a smaller population.
WhenTreatment planning for cancers where multiple active drugs exist — lymphoma, prostate, ovarian, small cell lung cancer.
DoseSequential standard-dose agents; the population-size trigger for introducing each subsequent agent is the variable.
For whomOncologists designing multi-agent regimens for any solid tumor or hematologic malignancy where multiple active drugs exist.
WhyAt 10 billion cells, statistical certainty exists that cells resistant to any given mechanism are present. At 10 million, this is 1000-fold less likely. At 100,000, near-certain absence of pre-existing resistance to a novel agent. Concurrent multi-drug regimens hit a population that already contains multi-resistant clones; sequential application hits a smaller, less diverse population.
Gatenby presents the math: 'Suppose you give one drug, get it to 10 million cells. Add the second drug. Knock it down again, give a third drug at a hundred thousand.' The denominator reduction exponentially reduces the probability of pre-existing multi-drug resistance. The pediatric leukemia cure protocol implicitly uses this logic — induction, consolidation, maintenance are sequential for this reason, not merely for toxicity management.
so let's say you give one drug you get it you really do a great job you're down to a million cells. Now you add the second drug — what's the probability within this 10 million that you will have some resistance? Knock it down again, give a third drug — let's say a hundred thousand. So you see what I mean.
Use longitudinal imaging to track intra-tumoral eco-evolutionary dynamics instead of biopsy
WhatMonitor tumor response using serial radiologic imaging (CT, MRI, PET) to identify habitat heterogeneity — areas of varying blood flow, edema, necrosis — as a proxy for eco-evolutionary dynamics, rather than relying on single-timepoint biopsy.
WhenThroughout active treatment, especially during adaptive therapy cycling protocols.
For whomOncologists managing cancers under active treatment, particularly those implementing adaptive therapy protocols.
WhyBiopsy specimens are immediately removed from the selective environment that shaped them and begin evolving in vitro — they represent dead or dying cells and are not representative of the living population's distribution. Serial imaging is non-destructive and captures temporal evolution of the tumor ecosystem.
CaveatsCurrent imaging cannot resolve at cellular level. Requires bridging macroscopic imaging habitats to inferred cellular phenotypes. Circulating tumor DNA may complement imaging but comes with its own sampling biases (unclear whether ctDNA comes from dying sensitive cells or surviving resistant cells).
Gatenby draws on landscape ecology methods: satellite images of an ecosystem can define habitat types, and species distribution can be inferred from habitat rather than requiring exhaustive ground-level sampling. Areas of good versus poor blood flow visible on contrast-enhanced CT correspond to different selective environments — hypoxia-adapted phenotypes in poorly vascularized regions, fast-cycling in well-vascularized regions, immune-interface phenotypes at the tumor edge.
I think we have to use imaging as a way to look at the internal evolution over time. It's a non-destructive way to do it. But we have to be able to take the macroscopic scale images that we can get from radiologic studies and bridge the scale to a microscopic level.
Early cancer detection as a force multiplier for extinction protocols
WhatPrioritize multi-cancer early detection (liquid biopsy, enhanced imaging surveillance) for high-risk individuals to identify cancers when the cell population is in the millions rather than billions. At small population sizes, extinction protocols become feasible; at large populations, eradication is probabilistically near-impossible.
WhenPopulation-level screening; individual surveillance for high-risk patients.
For whomAnyone designing or making decisions about cancer screening programs; high-risk individuals with known germline mutations (BRCA, Lynch syndrome).
WhyA 100-billion-cell tumor has more cells than the entire human population of Earth. No single intervention can reliably eradicate a population that size. A tumor at one million cells is vulnerable to the same stochastic and Allee-effect extinction dynamics that have eliminated species in the wild.
CaveatsEarly detection creates false-positive burden and over-diagnosis risk, particularly for indolent cancers. Gatenby acknowledges limitations in commenting on screening policy beyond the evolutionary-fitness argument.
Breast cancer bone marrow biopsies in women undergoing mastectomy for apparently localized disease find cancer cells in 30–40% — yet not all develop bone metastases. The micro-metastatic population is naturally failing to establish due to stochastic and Allee-effect dynamics. This confirms that small populations are vulnerable and argues for catching more cancers in this window.
the smaller the population the more likely you could cause extinction. You're going after hunter-gatherer colonies rather than the United States of America — you have a much easier chance, and they've had far less time to accumulate mutations and are far less interconnected.
Require a resistance management plan for every new cancer drug before approval
WhatBefore a new oncology drug enters clinical use, require characterization of its resistance mechanisms and a protocol specifying how resistance will be managed — analogous to the EPA's mandated integrated pest management plans for new pesticides.
WhenAt the drug development and regulatory approval stage.
For whomRegulatory agencies, clinical trialists, drug developers, oncology policy makers.
WhyCancer drugs are currently approved without any knowledge of resistance mechanisms or resistance management strategy. Pesticide manufacturers have been legally required to submit such plans since the Nixon era. This regulatory gap is why every cancer drug eventually fails — resistance is predictable, its mechanisms are characterizable, and management strategies can be pre-planned.
if you were a pesticide manufacturer you are required by law to submit a resistance management plan... you can introduce cancer drugs — cancer drugs are routinely approved without any knowledge of what the resistance mechanism is much less how you're going to manage that in a patient.
What's new
Personal practice updates, fresh positions, predictions
8 items
Adaptive therapy pilot in metastatic prostate cancer: 30 vs. 14 months, 4 patients still cycling at 5 years
~slice 2
In a prospective pilot trial led by oncologist Jin Seong Zhang, patients treated with PSA-guided intermittent enzalutamide (withdrawn at 50% PSA reduction, restarted at pre-treatment level) achieved a median time to progression of 30 months, versus 14 months for contemporaneous standard-of-care controls — a 16-month gain. Four of 20 adaptive patients have now been cycling beyond five years.
Why this matters: Metastatic castration-sensitive prostate cancer almost universally progresses to castration resistance within two years on continuous androgen deprivation. Sustained cycling with the same off-patent drug at five years would be virtually unheard of under standard of care — and the mechanism is explicitly evolutionary, not pharmacologic.
Background
Standard of care had been continuous maximum-tolerated-dose androgen deprivation until radiographic progression. Gatenby's mathematical models predicted that by preserving a sensitive-cell reservoir, the sensitive population's fitness advantage over resistant cells (estimated at 7-fold in this study) would suppress resistant expansion during drug-free windows.
The trial's biggest methodological flaw, as Gatenby explains, was lagging the PSA-triggered withdrawal by two months because insurance required radiographic confirmation before therapy change. This over-treated patients — killing too many sensitive cells — and still produced a 16-month survival advantage. The math model retrospectively showed that had the team relied solely on PSA and switched at exactly 50%, every patient in both cohorts could theoretically have achieved indefinite tumor control. The four long-term survivors were the subset whose treatment cycles happened to hit the optimal sensitive-to-resistant ratio across three successive cycles.
the median time progression for standard of care was 14 months which is pretty much what's in the literature. For the adaptive therapy group it was 30 months which was great. But then we said of the 20, four patients are now out five years and they're still cycling.
Also said
“if we had cut back on therapy we would have done still better and the models predicted that every patient in both cohorts in this study could have had control of the tumor indefinitely”— The model self-critique: even the suboptimal protocol beat standard of care, and the optimal version was theoretically curative for all.
Resistance costs fitness: the 7-fold sensitive-cell advantage drives resistant-cell extinction
~slice 2
The critical parameter the Gatenby lab measured retrospectively from the prostate trial was the fitness ratio of sensitive to resistant cells in the absence of drug. They estimated 2–3 before the trial; the data revealed 7. At this ratio, three consecutive optimal adaptive cycles are sufficient to push resistant cells toward extinction — not just control, but actual eradication.
Why this matters: For decades oncology accepted resistance as inevitable. The 7-fold fitness cost shows that drug resistance is not free: resistant cells carry molecular machinery (efflux pumps, DNA repair) that is metabolically expensive. Remove the drug, and sensitive cells — freed of competitive suppression by prior treatment — will outcompete and extinguish resistant clones.
Background
In integrated pest management, farmers discovered the same dynamic: leaving one quarter of a field untreated allowed pesticide-sensitive insects to re-expand, exploit their fitness advantage, and dilute the resistant fraction back toward baseline.
Gatenby describes the mechanism as competing for 'space and substrate' in a nutrient-poor tumor microenvironment. When drug is absent, resistant cells carry the metabolic overhead of their resistance machinery without any selective benefit — the fitness ratio flips against them. Three successive cycles at the optimal tipping point (somewhere around a 5–7 fold fitness ratio) were sufficient in the four long-term survivors to drive resistant population to extinction or near-extinction. None of the other patients in either cohort achieved three clean cycles.
the ratio of the fitness measure for the sensitive cells was seven fold that of the resistant cells and we had estimated at two or three. When the sensitive cells go down resistant cells go up, sensitive cells go up we expected them to plateau but in fact they're going down but seven. Three successive cycles is a critical enough mass that you can drive that resistance cell to a presumably to a place where... progressively went toward extinction.
Cancer cells grow at the same rate as normal cells — the difference is cell-cycle signaling, not proliferation speed
~slice 3
The canonical medical-school answer that 'cancer cells grow faster than normal cells' is wrong at multiple levels. Normal cells respond to stop-dividing signals; cancer cells do not. The proliferation rate itself is not systematically elevated — the failure of growth control is the defining feature.
Why this matters: Chemotherapy's logic — target dividing cells — is built on this misunderstanding. It is why chemo hits rapidly dividing normal tissue (mucosa, hair follicles) as collateral damage, and why its selectivity for cancer is always incomplete.
Gatenby frames this as a self-defined fitness function: cancer cell proliferation is dependent on its own internal signals rather than tissue-level instructions. This is why cancer can evolve — normal tissue cannot, because its birth and death rates are tissue-controlled, not cell-autonomous. The moment a lineage escapes tissue control it enters Darwinian competition. The medical catechism 'cancers grow faster' is not only wrong, it is strategically misleading because it implies that faster-proliferating cells are the target, when the real target is the autonomous growth-decision circuit.
a normal cell doesn't divide slower it just when it's told to stop dividing it stops dividing. The cancer cell doesn't — when it's told to stop dividing it says piss off I'm going to keep dividing.
Integrated pest management applied to cancer: the diamondback moth precedent from the 1970s
~slice 2
The diamondback moth, having been exposed to every pesticide developed in the modern era, became resistant to all of them by the 1980s. The Nixon-era EPA response — integrated pest management (IPM) — shifted from maximum-dose eradication to managing pest populations below economically damaging thresholds. Gatenby directly transposes this logic to oncology: stop trying to eradicate, start managing.
Why this matters: Pesticide manufacturers are legally required to submit a resistance management plan before a new product reaches market. Cancer drugs require no such plan. The ecological field was decades ahead.
Background
IPM used partial field treatment (three quarters pesticide, one quarter untreated) to maintain a sensitive-insect reservoir. Sensitive insects in the untreated quarter, carrying no resistance machinery, had a fitness advantage and re-expanded into treated areas — diluting the resistant fraction each season.
Gatenby notes the precise parallel to his prostate trial: the untreated quarter of the field is the drug-free window, the sensitive insects are sensitive cancer cells, and the fitness-cost logic is identical. The major difference is that cancer cells live in a resource-limited microenvironment whereas field insects have open-field dispersal — but the population dynamics are the same. Gatenby: 'If it's too complicated to model, you have to have mathematics. The argument is self-defeating.'
if you were a pesticide manufacturer you are required by law to submit a resistance management plan... you can introduce cancer drugs — cancer drugs are routinely approved without any knowledge of what the resistance mechanism is much less how you're going to manage that in a patient.
Extinction vortex: sequential perturbations, not a magic bullet, drive cancer to extinction
~slice 3
Anthropocene extinctions — caused by humans eliminating other species — are almost never single-event. They are multi-cause, multi-event processes: the species is first reduced to a fragmented small population by one perturbation, then a cascade of smaller stressors (bad winter, fire, disease, Allee-effect collapse of cooperative behaviors) completes the extinction. Gatenby argues cancer therapy should follow the same playbook.
Why this matters: The entire cancer drug development industry is organized around finding a magic bullet — the one drug or target that eradicates the cancer. The ecology of extinction says this is the wrong model: the dinosaur-killer asteroid is the historical exception, not the rule, and its collateral damage is catastrophic.
Background
When a population is fragmented and small, stochastic fluctuations in birth and death rates can cause extinction that would be impossible in a large population. Allee effects compound this: small cancer cell populations lose cooperative behaviors (angiogenic factor secretion, extracellular matrix building, immune evasion through collective signaling) that require a minimum group size.
Gatenby's boxing analogy: 'This is not a boxing match it's a knife fight. When you knock your opponent down you don't stand back and wait — you go attack.' The two-step model is: (1) first-strike therapy drives the tumor to near-undetectable levels, fragmenting it into small isolated subpopulations vulnerable to stochastic and Allee dynamics; (2) instead of continuing the same therapy, immediately hit with a sequence of additional perturbations — immunotherapy, metabolic challenges, second-line drugs — while the population is fragmented, can't mount collective resistance, and is subject to small-number extinction dynamics. This is how leukemia is cured in children: induction then immediate switch to different drugs then maintenance sequence.
what we've learned from anthropocene extinctions from our own species eradicating other species is that most extinctions are multi-cause multi-event. Not not it's not the dinosaurs — they are the exception not the rule. We should probably be thinking more about these multi-cause approaches rather than trying to find a magic bullet.
Also said
“there's this thing called the extinction vortex that they talk about in extinctions where when you've got a small population, there's typically a sequence of perturbations and they tend to be self-synergizing — the further down the population you push, the more sensitive it is to stochastic and Allee effects.”— Quantifies why the sequencing of perturbations at small tumor populations has disproportionate effect.
The eco-evolutionary tumor index: environment drives phenotype, not just genome
~slice 4
The dominant cancer genetics paradigm says random mutations accumulate, occasional ones provide fitness advantages, and the clone expands. Gatenby argues this misses the central evolutionary dynamic: heterogeneous microenvironments within the tumor (variable blood flow, competing with normal cells at the edge, competing with other tumor cells in the core) apply different selection forces that drive different phenotypes — and genes are consequences of evolution, not its cause.
Why this matters: Billions of dollars and decades of work have gone into characterizing tumor genomes. Gatenby suggests this is analogous to grinding up Galapagos finches and sequencing them — you could not reconstruct the Origin of Species from the data because the information that matters is the beak-to-environment phenotypic match, not the genes downstream.
Tumor 'species' arise through speciation driven by environmental niches — hypoxic core, vascularized edge, immunologically active periphery. Cell line studies compound this problem: cancer cells taken out of a patient and grown in a dish immediately leave their selective environment, losing the eco-evolutionary forces that shaped them. Literature built on cell lines is studying cells that have evolved far past in-vivo relevance. The practical implication: tumor heterogeneity maps to environmental heterogeneity, not just mutational chance, and interventions that alter the microenvironment (anti-VEGF, metabolic challenges, acidity modulation) can shift which phenotypes are selected for.
the genes aren't causing the evolution — the genes are the consequences of evolution. The different environments within the tumor are the ones that give rise to different phenotypes which in turn give rise to different genotypes.
PSA-guided cycling exposes a systematic flaw: over-treating past the 50% threshold kills sensitive-cell suppression
~slice 2
The prostate trial required radiographic confirmation after PSA hit 50% — creating a 2-month lag during which therapy continued and sensitive cells were driven lower than the model required. This destroyed the competitive pressure sensitive cells needed to suppress resistant cells. The math model predicted the corrected protocol would have achieved indefinite control in all patients.
Why this matters: Insurance reimbursement constraints — not biology — may be the single largest modifiable driver of treatment failure in adaptive therapy. This is a solvable regulatory problem, not a scientific one.
we required that when the psa went down it would be confirmed by radiographic studies... we didn't change therapy until we got the radiographic exchange so we were lagging for two months. We were killing off too many of the sensitive cells and therefore they were not able to impede the fitness of the resistant cells.
Immunotherapy as the closer: most effective after cytoreduction, when tumor is fragmented and Allee effects are maximal
~slice 3
Immunotherapy works as a standalone magic bullet only in the minority of tumors with high mutational burden or MSI-H status. For most tumors, Gatenby's group frames immunotherapy as the final perturbation in a sequential protocol: use it when the tumor has been driven to a small, fragmented population, because Allee effects reduce cancer cells' collective ability to evade immune surveillance at small population sizes.
Why this matters: The sequencing insight changes the immunotherapy question from 'does it work?' to 'when in the treatment sequence does it work best?' — the answer being: after cytoreduction, not upfront as monotherapy in large tumors.
Supporting evidence: a p53 vaccine trial in multiply-treated lung cancer patients generated immune cells but achieved minimal tumor response. Those same patients then received chemotherapy with a 60–70% response rate — dramatically higher than the expected less-than-5% at that treatment stage. The patients with the best immune response to the vaccine were the most chemotherapy-responsive, suggesting the vaccine forced adaptive resistance strategies that made cells vulnerable to cytotoxic agents. Gatenby's framing: use the first-strike therapy to create a resistant phenotype you already know how to exploit, then deliver the coup de grace.
bringing the immune system in when you've got the tumor on the mat — it's small, fragmented — I think that will be the most effective closer that we have to essentially wipe it out.
Also said
“cells that survive chemotherapy are more vulnerable to immunotherapy and ultimately that would be the game that you'd want to play here”— The sequencing principle: surviving chemo cells are phenotypically committed to resistance strategies that expose new immunological vulnerabilities.
Recommendations
Products, supplements, and tools mentioned in the episode
4 items
Robert Gatenby's evolutionary oncology collaboration (Moffitt Cancer Center)
Service
For patients with metastatic prostate cancer or other cancers who have failed standard therapy or want an evolutionary approach, Gatenby offers to work with oncologists to model eco-evolutionary dynamics of specific cases — though he cannot prescribe directly.
Gatenby is explicit that he is not an oncologist and cannot prescribe. His offer is to collaborate with oncologists on mathematical modeling of a patient's specific tumor dynamics. The practical challenge is that most oncologists remain unwilling to deviate from standard protocols due to medical-legal risk.
when people call me I said I'm happy to work with your oncologist if your oncologist is willing to try something different — I'm happy to at least give them my best sense for what the underlying eco-evolutionary dynamics are.
PSA-guided adaptive cycling for newly diagnosed metastatic prostate cancer
Practice
For men newly diagnosed with metastatic castration-sensitive prostate cancer, adaptive therapy cycling abiraterone or enzalutamide guided by PSA 50% threshold rather than continuous dosing is available at some academic centers with oncologists willing to deviate from standard of care.
The pilot trial used abiraterone acetate, now off-patent. A phase III trial is being funded by a European philanthropic organization. Gatenby names Jin Seong Zhang as the oncologist who ran the original pilot — an act of clinical courage against institutional grain. The metabolic damage of continuous ADT (insulin resistance, fatty liver, sarcopenia) is severe; avoiding it through cycling is a secondary benefit beyond cancer control.
you have to find an oncologist willing to do this. There are some who will work with them but there's a lot that will not.
Demand a sequential perturbation plan when you achieve complete or near-complete response to first-line therapy
Practice
Patients achieving major or complete response to first-line therapy (PSA normalization, bone marrow clearance, radiographic complete response) should ask: what is the next agent, and when will you introduce it? Continuing the same drug after maximal response is the mechanism by which adaptive resistance develops.
Gatenby identifies men with metastatic prostate cancer who normalize PSA on ADT as the paradigmatic missed opportunity: 90%+ achieve PSA undetectability, standard care continues indefinite ADT until castration resistance emerges — with enormous metabolic collateral damage along the way. The evolutionary strategy would be to immediately introduce a second agent targeting a different pathway while the tumor is at its smallest.
when as soon as it normalizes we should use additional therapies — hit it again. This is the knife fight again. We should use additional therapies and that's a very common disease and a very common scenario.
Referenced as the historical case study for why medical communities resist paradigm shifts — Semmelweis died in an insane asylum after proposing hand washing, and the medical community did not adopt aseptic technique within his lifetime. The parallel to evolutionary oncology's reception is explicit and sobering.
Attia raises the book to contextualize Gatenby's experience — his articles are being rejected for the tenth time, oncologists call his models 'ridiculous', and a phase III trial in prostate cancer is being funded by European philanthropy rather than pharma or NIH. The Semmelweis parallel is not rhetorical: the resistance is primarily psychological and economic, not intellectual.
even moving the medical community toward washing hands or using aseptic technique did not occur overnight — in fact it occurred over decades. The individual who first proposed it basically dies in an insane asylum for having been so rejected.
Lines worth pulling out — contrarian, specific, or perfectly phrased
6 items
the scripted question was why do cancers grow and the scripted answer was because cancer cells grow faster than normal cells. That's totally wrong — at so many levels that it's sort of hard to believe.
Gatenby's opening salvo: the foundational premise of cancer treatment is wrong, and he was taught it in medical school as catechism.
it's not a boxing match it's a knife fight. When you knock your opponent down you don't stand back and wait — you go attack. That's an approach we've called an extinction approach.
The single most memorable distillation of the extinction-protocol strategy — shift from damage-avoidance to aggressive sequential perturbation after cytoreduction.
in cancer we're always looking for the magic bullet — the one that will eradicate the cancer. For a century we've been looking for magic bullets but maybe all we need is a series of pretty good bullets.
Reframes the entire 50-year war on cancer: the search for a single knockout drug is the wrong model; sequential perturbation is the correct one.
evolution is very clever and likes to embarrass you. It's not random either — there's predictability to it. Finding that point where you can predict with reasonable certainty and also sort of hedge your bets.
Gatenby's honest statement of the limits of modeling combined with its utility — the right epistemic posture for complex biological systems.
the genes aren't causing the evolution — the genes are the consequences of evolution. The different environments within the tumor are the ones that give rise to different phenotypes which in turn give rise to different genotypes.
Inverts the dominant cancer genomics paradigm: environment drives phenotype drives genotype, not the reverse. Darwin saw the beak-to-seed match; sequencing the birds alone would not have revealed it.
in non-linear systems your intuition can be very misleading — and that's true in life, of which biology especially this corner of biology happens to be exceedingly non-linear.
The episode's closing statement and the core epistemological claim of evolutionary oncology.
Sign in to share feedback
Tell us if this brief hit the mark or missed it — feedback feeds back into the next iteration of the prompt.
Reading is free for everyone. A free account adds the personal layer: save protocols, follow experts, and see how the other experts weigh in on this same topic.
Educational summary of the cited expert source — not medical advice. Open the source recording linked above and consult a qualified physician before acting on any protocol.
